Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 18F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis.

Literature DB >> 27071998

¹⁸F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis.

Osamu Manabe¹, Kenji Hirata², Okamoto Shozo², Tohru Shiga², Yuko Uchiyama², Kentaro Kobayashi², Shiro Watanabe², Takuya Toyonaga², Hisaya Kikuchi², Noriko Oyama-Manabe³, Nagara Tamaki².

Abstract

18F-fluoromisonidazole (FMISO) is a positron emission tomography (PET) tracer that accumulates in hypoxic tissues. We here present a case of suspected cardiac sarcoidosis which was detected with increased FMISO uptake.

Entities: Chemical Disease

Keywords: FDG; FMISO; cardiac sarcoidosis; inflammation

Mesh：

Substances：

Year: 2016 PMID： 27071998 DOI： 10.1007/s12350-016-0495-2

Source DB: PubMed Journal: J Nucl Cardiol ISSN： 1071-3581 Impact factor: 5.952

8 in total

Review 1. Sarcoidosis.

Authors: Michael C Iannuzzi; Benjamin A Rybicki; Alvin S Teirstein
Journal: N Engl J Med Date: 2007-11-22 Impact factor: 91.245

2. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.

Authors: David H Birnie; William H Sauer; Frank Bogun; Joshua M Cooper; Daniel A Culver; Claire S Duvernoy; Marc A Judson; Jordana Kron; Davendra Mehta; Jens Cosedis Nielsen; Amit R Patel; Tohru Ohe; Pekka Raatikainen; Kyoko Soejima
Journal: Heart Rhythm Date: 2014-05-09 Impact factor: 6.343

3. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.

Authors: Nobuyuki Kawai; Wei Lin; Wei-Dong Cao; Daisuke Ogawa; Keisuke Miyake; Reiji Haba; Yukito Maeda; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-30 Impact factor: 9.236

4. Expression of HIF-1A/VEGF/ING-4 Axis in Pulmonary Sarcoidosis.

Authors: W J Piotrowski; J Kiszałkiewicz; D Pastuszak-Lewandoska; P Górski; A Antczak; M Migdalska-Sęk; W Górski; K H Czarnecka; D Domańska; E Nawrot; E Brzeziańska-Lasota
Journal: Adv Exp Med Biol Date: 2015 Impact factor: 2.622

5. Elevated (18)F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis.

Authors: Osamu Manabe; Hiroshi Ohira; Keiichiro Yoshinaga; Takahiro Sato; Alisa Klaipetch; Noriko Oyama-Manabe; Yoichi M Ito; Ichizo Tsujino; Masaharu Nishimura; Nagara Tamaki
Journal: Eur J Nucl Med Mol Imaging Date: 2013-05-29 Impact factor: 9.236

6. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium.

Authors: M E Shelton; C S Dence; D R Hwang; P Herrero; M J Welch; S R Bergmann
Journal: J Am Coll Cardiol Date: 1990-08 Impact factor: 24.094

7. (18)F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors.

Authors: Takuya Toyonaga; Kenji Hirata; Shigeru Yamaguchi; Kanako C Hatanaka; Sayaka Yuzawa; Osamu Manabe; Kentaro Kobayashi; Shiro Watanabe; Tohru Shiga; Shunsuke Terasaka; Hiroyuki Kobayashi; Yuji Kuge; Nagara Tamaki
Journal: Eur J Nucl Med Mol Imaging Date: 2016-02-03 Impact factor: 9.236

8. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial (18)F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis.

Authors: Osamu Manabe; Keiichiro Yoshinaga; Hiroshi Ohira; Atsuro Masuda; Takahiro Sato; Ichizo Tsujino; Asuka Yamada; Noriko Oyama-Manabe; Kenji Hirata; Masaharu Nishimura; Nagara Tamaki
Journal: J Nucl Cardiol Date: 2015-08-05 Impact factor: 5.952

8 in total

7 in total

¹⁸F-fluoromisonidazole (FMISO) PET may have the potential to detect cardiac sarcoidosis.

Review 1. Sarcoidosis.

2. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.

3. Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas.

4. Expression of HIF-1A/VEGF/ING-4 Axis in Pulmonary Sarcoidosis.

5. Elevated (18)F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis.

6. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium.

7. (18)F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors.

8. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial (18)F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis.

1. Multimodality imaging in the diagnosis and management of cardiac sarcoidosis.

Review 2. The role of positron emission tomography in the assessment of cardiac sarcoidosis.

Review 3. Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation.

Review 4. Current State and Future Directions of Multimodality Imaging in Cardiac Sarcoidosis.

Review 5. PET Imaging of Cardiac Hypoxia: Hitting Hypoxia Where It Hurts.

6. Radiopharmaceutical tracers for cardiac imaging.

Review 7. Advances in Diagnostic Imaging for Cardiac Sarcoidosis.